Auna S.A. (AUNA)vsEli Lilly and Company (LLY)
AUNA
Auna S.A.
$5.07
-0.78%
HEALTHCARE · Cap: $385.09M
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1386% more annual revenue ($65.18B vs $4.39B). LLY leads profitability with a 31.7% profit margin vs 2.2%. AUNA trades at a lower P/E of 13.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
AUNA
Hold49
out of 100
Grade: D+
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 6.5% — below average capital efficiency
2.2% margin — thin
Earnings declined 50.9%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AUNA
The strongest argument for AUNA centers on Price/Book, P/E Ratio.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.23 is elevated, increasing financial risk. Thin 2.2% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
AUNA profiles as a value stock while LLY is a growth play — different risk/reward profiles.
AUNA carries more volatility with a beta of 1.64 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 49/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a prominent telecommunications and digital services provider in Latin America, specializing in integrated solutions that enhance connectivity and customer experience. With a comprehensive portfolio that includes high-speed internet, television, and mobile services, Auna caters to both residential and business clients across a variety of markets. The company's dedication to innovation and exceptional customer service has established it as a key player in the region's dynamic digital landscape. Its extensive and robust infrastructure positions Auna favorably to leverage the growing demand for advanced telecom solutions, presenting significant growth opportunities for institutional investors.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?